How should asymptomatic hypertension be managed in the hospital?
Other studies have examined the role of oral antihypertensives for management of asymptomatic hypertension in the inpatient setting. A systematic review and meta-analysis by Souza et al. assessed the use of oral pharmacotherapy for hypertensive urgency.11 Sixteen randomized clinical trials were reviewed and it was determined that angiotensin-converting enzyme inhibitors (ACE-I) had a superior effect in treating hypertensive urgencies.11 The most common side effect of using an ACE-I was a bad taste in patient’s mouths, and researchers did not observe side effects that were similar as those seen with the use of IV antihypertensives.11
Further, Jaker et al. performed a randomized, double-blind prospective study comparing a single dose of oral nifedipine with oral clonidine for the treatment of hypertensive urgency in 51 patients.12 Both the oral nifedipine and oral clonidine were extremely effective in reducing blood pressure fairly safely.12 However, the rapid lowering of blood pressure with oral nifedipine was concerning to Grossman et al.13 In their literature review of the side effects of oral and sublingual nifedipine, they found that it was one of the most common therapeutic interventions for hypertensive urgency or emergency.13 However, it was potentially dangerous because of the inconsistent blood pressure response after nifedipine administration, particularly with the sublingual form.13 CVAs, acute MIs, and even death were the reported adverse events with the use of oral and sublingual nifedipine.13 Because of that, the investigators recommend against the use of oral or sublingual nifedipine in hypertensive urgency or emergency and suggest using other oral antihypertensive agents instead.13
Typically, if the patient’s blood pressure remains elevated despite these efforts, no urgent treatment is indicated and we recommend close monitoring of the patient’s blood pressure during the hospitalization. If hypertension persists, the next best step would be to titrate a patient’s current oral antihypertensive therapy or to start a long-acting antihypertensive therapy per the JNC 8 (Eighth Joint National Committee) guidelines. It should be noted that, in those patients that are high risk, such as those with known coronary artery disease, heart failure, or prior hemorrhagic CVA, a short-acting oral antihypertensive such as captopril, carvedilol, clonidine, or furosemide should be considered.
